JNJ vs ONC: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
JNJ is the larger of the two ($617.78B market cap): the incumbent the market prices for continued execution (20.07x forward earnings, beta 0.23). ONC is the smaller challenger ($41.76B), actually pricier on forward earnings (35.90x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
JNJ vs ONC: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | JNJ | ONC | What it tells you |
|---|---|---|---|
| Market cap | $617.78B | $41.76B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 20.07 | 35.90 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 29.77 | 66.16 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.23 | 0.50 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 83% of range | 88% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 7.27 | 7.96 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: JNJ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how JNJ and ONC affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and ONC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and ONC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Johnson & Johnson (JNJ) do?
Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.
What does BeOne Medicines (ONC) do?
BeOne Medicines is a global oncology company built around one large drug. BRUKINSA (zanubrutinib), a BTK inhibitor used in chronic lymphocytic leukemia and other B-cell cancers, produced ~$1.2 billion of the ~$1.68 billion in product revenue it booked in the second quarter of 2026. Around it sit TEVIMBRA (tislelizumab), a PD-1 antibody; BEQALZI (sonrotoclax), a BCL2 inhibitor that won U.S. accelerated approval in relapsed or refractory mantle cell lymphoma; ZIIHERA (zanidatamab) in HER2-positive gastroesophageal cancer; and in-licensed Amgen products sold in China. The company was BeiGene until recently. Its Nasdaq listing began trading under symbol ONC instead of BGNE on January 2, 2025, and effective May 27, 2025 the company moved its jurisdiction of incorporation from the Cayman Islands to Switzerland and took the BeOne Medicines name. What a U.S. holder actually owns is an American Depositary Share representing 13 ordinary shares, the same shares listed in Hong Kong (06160) and, as RMB shares, on Shanghai's STAR Market (688235).
JNJ vs ONC: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
- ONC drivers: BRUKINSA taking share in B-cell cancers; Costs growing slower than revenue.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For ONC, concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business.
JNJ or ONC: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JNJ if you believe its drivers more; ONC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and ONC guides.
JNJ vs ONC: the full fundamentals
JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.
ONC. Figures come from the Form 10-Q for the quarter ended June 30, 2026 and the accompanying Q2 2026 earnings release filed with the SEC on August 5, 2026. The company reports in U.S. dollars, so no conversion is involved despite the Swiss domicile and the Hong Kong and Shanghai listings. Note that per-ADS figures are 13 times the per-ordinary-share figures, which is why a screener showing EPS of $0.16 and one showing $2.12 can both be right.
Headline figures (approximate, early 2026): JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x; ONC shows revenue (ttm) ~$6.13B, q2 2026 revenue ~$1.71B, up ~30% year over year, gaap net income (ttm) ~$656M (FY2025 was ~$287M, FY2024 a ~$645M loss), q2 2026 diluted eps per ads ~$2.05 GAAP, ~$3.84 adjusted.
The bottom line: JNJ vs ONC
JNJ and ONC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JNJ and ONC exposure against your real portfolio. It is not an investment adviser.
Wondering how JNJ or ONC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Johnson & Johnson with AI
Connect the broker you already use and ask Walnut's AI how JNJ fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between JNJ and ONC?
+
Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). BeOne Medicines is a global oncology company built around one large drug. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is JNJ or ONC the better stock?
+
Neither is universally better. JNJ is the larger incumbent; ONC is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, JNJ or ONC?
+
On forward P/E (as of August 2026), JNJ trades at 20.07x and ONC at 35.90x, so JNJ is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both JNJ and ONC?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of JNJ vs ONC?
+
JNJ: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. Drug pricing pressure, including US government negotiation of certain drug prices, can weigh on margins. The company also faces significant legal liability, most notably ongoing litigation related to talc-based products, which has created uncertainty and large potential settlements. MedTech competes in tough device markets and is exposed to hospital budgets and procedure volumes. Regulatory, clinical-trial, and product-safety risks are inherent to healthcare. Growth is steady rather than rapid, so J&J is valued as a defensive compounder rather than a high-growth name. ONC: Concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. Zydus filed an ANDA with Paragraph IV certifications against certain BRUKINSA Orange Book patents in early 2026, though it has not challenged the composition of matter patent that runs to 2034. AbbVie's trade secret complaint over the BTK degrader program, including tacabrutideg, survived a motion to dismiss on May 12, 2026 and remains pending with no trial date. About 30% of revenue and a large share of manufacturing and clinical operations sit in China, leaving the company exposed to tariffs, trade-status changes and U.S. or Chinese action against firms with large operations in both. The valuation, near 64 times trailing GAAP earnings on a profit record barely a year old, assumes the growth and the margin improvement both continue.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell JNJ or ONC; figures are approximate and dated (as of August 2026). Verify current data before investing.